source
- Third patient dies in Chinese trial of RiboX Therapeutics' experimental genetic therapyA patient with an autoimmune disease died after receiving an experimental genetic medicine from RiboX Therapeutics, a Shanghai‑based biotech startup. The death marks the third fatality reported in…
- LEO Pharma spends $435 million to acquire rare-disease skin drug dersimelagonLEO Pharma announced it will pay $435 million to buy the rights to dersimelagon, an oral MC1R agonist originally developed by Tanabe Pharma. The drug has completed Phase 3 trials for two rare phot…